ATE465149T1 - Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen - Google Patents

Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen

Info

Publication number
ATE465149T1
ATE465149T1 AT97907937T AT97907937T ATE465149T1 AT E465149 T1 ATE465149 T1 AT E465149T1 AT 97907937 T AT97907937 T AT 97907937T AT 97907937 T AT97907937 T AT 97907937T AT E465149 T1 ATE465149 T1 AT E465149T1
Authority
AT
Austria
Prior art keywords
immunophilin
chimeric proteins
rapamycin derivatives
derived domain
multimerizing agents
Prior art date
Application number
AT97907937T
Other languages
English (en)
Inventor
Dennis Holt
Terence Keenan
Tao Guo
Edgardo Laborde
Wu Yang
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Application granted granted Critical
Publication of ATE465149T1 publication Critical patent/ATE465149T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97907937T 1996-02-28 1997-02-28 Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen ATE465149T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1243296P 1996-02-28 1996-02-28
US2486196P 1996-08-28 1996-08-28
US3303596P 1996-12-10 1996-12-10
PCT/US1997/003137 WO1997031898A1 (en) 1996-02-28 1997-02-28 Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains

Publications (1)

Publication Number Publication Date
ATE465149T1 true ATE465149T1 (de) 2010-05-15

Family

ID=27359637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907937T ATE465149T1 (de) 1996-02-28 1997-02-28 Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen

Country Status (7)

Country Link
EP (1) EP0888303B1 (de)
JP (2) JP4936345B2 (de)
AT (1) ATE465149T1 (de)
AU (2) AU731826B2 (de)
CA (1) CA2244363C (de)
DE (1) DE69739853D1 (de)
WO (2) WO1997031898A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731826B2 (en) * 1996-02-28 2001-04-05 Ariad Pharmaceuticals, Inc. Synthetic Multimerizing Agents
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
JP2002503667A (ja) * 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
WO1999050425A2 (en) * 1998-03-30 1999-10-07 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors
CN101245043B (zh) * 1998-06-03 2013-02-13 Gpinil控股公司 N-杂环化合物的羧酸和羧酸电子等排物
EA008723B1 (ru) * 1998-06-03 2007-06-29 Джи-Пи-Ай Эн-Ай-Эл Холдингз, Инк. Аза-гетероциклические соединения, применяемые для лечения неврологических расстройств и выпадения волос
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
CA2343917A1 (en) 1998-10-19 2000-04-27 Ariad Gene Therapeutics, Inc. Materials and methods involving conditional retention domains
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
BR0012327A (pt) 1999-07-09 2002-07-02 Ortho Mcneil Pharm Inc Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
AU6388500A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Multivalent sulfonamides
AU6499000A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Multivalent compounds
AU6611800A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Method of treating hair loss using multivalent ketoamides and amides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
EP1125925A1 (de) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amin-Derivate zur Behandlung von Apoptosis
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
ES2249986B1 (es) * 2004-07-02 2007-02-01 Universidad Complutense De Madrid Sintesis de derivados fluorescentes de tacrolimus (fk506) y su uso en la caracterizacion de la interaccion de fk506 con proteinas de union a fk506.
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
WO2012145572A1 (en) 2011-04-20 2012-10-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2013186264A1 (en) 2012-06-12 2013-12-19 Universitätsspital Basel Immortalized mesenchymal stem cells that can be killed through an inducible apoptosis system
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
CN103242218B (zh) * 2013-05-24 2015-04-15 深圳市天和医药科技开发有限公司 N-取代哌可酸衍生物及其制备方法与应用
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
RU2021118125A (ru) 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CN109153975A (zh) 2015-12-28 2019-01-04 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
US11186839B2 (en) 2016-11-21 2021-11-30 Tribiotica Llc Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations
CN110121559A (zh) 2016-11-21 2019-08-13 特里比奥迪卡有限责任公司 通过模板化组装反应进行蛋白质的定向折叠组装或二聚化的方法
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
PT3589730T (pt) 2017-02-28 2024-02-28 Univ Pennsylvania Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
UY37620A (es) 2017-02-28 2018-08-31 Univ Pennsylvania Vacunas contra la gripe mediadas por aav novedosas
US11939379B2 (en) 2017-05-19 2024-03-26 The Regents Of The University Of California Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
EP3788369A1 (de) 2018-05-01 2021-03-10 Novartis Ag Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
EP3801769A1 (de) 2018-05-25 2021-04-14 Novartis AG Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car)
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
EP4635978A2 (de) 2018-08-31 2025-10-22 Novartis AG Verfahren zur herstellung von chimären antigenrezeptorexprimierenden zellen
EP3844265A2 (de) 2018-08-31 2021-07-07 Novartis AG Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CN109734655B (zh) * 2019-03-11 2020-06-02 都创(上海)医药科技有限公司 一种fkbp配体的同型二聚体合成工艺
EP3953455A1 (de) 2019-04-12 2022-02-16 Novartis AG Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
EP4104187A1 (de) 2020-02-14 2022-12-21 Novartis AG Verfahren zur vorhersage des ansprechens auf eine chimäre antigen-rezeptor-therapie
EP4110376A2 (de) 2020-02-27 2023-01-04 Novartis AG Verfahren zur herstellung von zellen mit expression des chimären antigenrezeptors
CA3198447A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
TW202237850A (zh) 2020-12-01 2022-10-01 賓州大學委員會 具有組織特異性靶向基序的新穎構成物及含有其之組成物
CA3216004A1 (en) 2021-04-23 2022-10-27 The Trustees Of The University Of Pennsylvania Novel compositions with brain-specific targeting motifs and compositions containing same
EP4409010A1 (de) 2021-10-02 2024-08-07 The Trustees of The University of Pennsylvania Neue aav-kapside und diese enthaltende zusammensetzungen
CN119317718A (zh) 2022-01-25 2025-01-14 宾夕法尼亚州大学信托人 用于改善心脏转导和肝脏去靶向的aav衣壳
CA3266372A1 (en) 2022-09-15 2024-03-21 Novartis Ag TREATMENT OF AUTOIMMUNE DISORDERS USING CHIMERIC ANTIGEN RECEPTOR THERAPY
EP4634394A2 (de) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Rekombinante aav-mutantenvektoren mit herz- und skelettmuskelspezifischen zielmotiven und zusammensetzungen damit
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
TW202516019A (zh) 2023-06-29 2025-04-16 賓州大學委員會 具中樞神經系統靶向模體的突變aav及含有其之組成物
WO2025102034A1 (en) 2023-11-10 2025-05-15 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome
WO2025106661A1 (en) 2023-11-14 2025-05-22 The Trustees Of The University Of Pennsylvania Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
EP0804561B1 (de) * 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulierte transkription von zielgerichteten genen und andere biologische ereignisse
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
DE69534300T2 (de) * 1994-08-18 2006-05-18 Ariad Gene Therapeutics, Inc., Cambridge Neues multimerisierendes reagenz
AU731826B2 (en) * 1996-02-28 2001-04-05 Ariad Pharmaceuticals, Inc. Synthetic Multimerizing Agents

Also Published As

Publication number Publication date
WO1997031899A1 (en) 1997-09-04
EP0888303B1 (de) 2010-04-21
CA2244363A1 (en) 1997-09-04
DE69739853D1 (de) 2010-06-02
EP0888303A1 (de) 1999-01-07
AU1980997A (en) 1997-09-16
AU2192797A (en) 1997-09-16
WO1997031898A1 (en) 1997-09-04
CA2244363C (en) 2006-11-14
JP4936345B2 (ja) 2012-05-23
JP2000505475A (ja) 2000-05-09
AU731826B2 (en) 2001-04-05
JP2012131794A (ja) 2012-07-12

Similar Documents

Publication Publication Date Title
ATE465149T1 (de) Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
EP0776327A4 (de) Neues multimerisierendes reagenz
MY118498A (en) Lactam derivatives
BR9510420A (pt) Azetidin-2-onas substituìdas para o tratamento de aterosclerose
ATE218859T1 (de) Liganden des neuropeptids y
DK0778277T3 (da) Substituerede heterocycliske derivater som CRF antagonister
EA200000048A1 (ru) ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ
DE69331774D1 (de) 7-Substituierte-8-substituierte-9-substituierte Amino-7-Demethyl-6-Deoxy-Tetracycline als antibiotische Mittel
ES2187660T3 (es) Derivados de rapamicina.
PL341239A1 (en) Dihydrobenzofuranes
MX9500228A (es) N-oxidos de 4-arilpiperazinas y 4-arilpiperidinas.
ATE326512T1 (de) Mischungen von beta-hydroxyalkylamiden und ihre verwendung als vernetzungsmittel bei der herstellung von pulverlacken
ATE167664T1 (de) Verwendung von aminen in ölzusammensetzungen
DE69017627D1 (de) Isochinolinderivate und ihre Salze als Proteasehemmer.
AU3577295A (en) Reagent for the determination of free radicals
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
EP0987247A4 (de) Itaconatderivate und ihre anwendung als komponente in einem polymer
TW340788B (en) Ester compounds and household insects-controlling agents containing the same as an active ingredient

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties